America Great Health

What they do

The company, formerly Crown Marketing, was renamed America Great Health in 2017 after a change of control by an investor group led by Mike Q. Wang. It operates through subsidiaries including a wholly owned California subsidiary, a China subsidiary (Meizhong Health Industry Development Co., Ltd.) focused on M&A, investments, financing and marketing of medical equipment and health products, and Nutrature Health LLC, formed in 2021. Its stated activities center on health products, medical equipment marketing, and licensing or development of anti-aging, stem cell and peptide technologies through partnerships.

Revenue drivers

• Health products / medical equipment marketing — Revenue is reported at the consolidated level only, with annual revenue rising from $104,648 in 2022 to $391,743 in 2025; the filings provided do not disclose a segment breakdown by product line or geography.
• China operations (Meizhong Health Industry Development Co., Ltd.) — A wholly owned China subsidiary registered in June 2019 engaged in M&A, investments and financings and marketing of medical equipment and health products in China; no separate revenue figure for this subsidiary is given.
• Sijinsai (Hainan) Biological Tech Ltd. joint venture — A China joint venture established in June 2021 with Brilliant Healthcare Limited for stem cell-related R&D, production, sales and raw material procurement; the company agreed to invest US$4.2 million over 24 months for 60% ownership, with $50,000 paid as a first investment on July 9, 2021. No revenue contribution is disclosed.
• Nutrature Health LLC — A 100% owned subsidiary set up November 4, 2021; the excerpts do not identify its products or any revenue attributed to it.

Recent performance

Annual revenue grew each year from $204,308 in 2023 to $294,670 in 2024 and $391,743 in 2025, but the company has reported net losses every year shown, including $719,119 in 2025 and $1.2 million in 2024. Operating cash flow has been negative each year, at -$332,862 in 2025 and -$615,627 in 2024. Quarterly revenue in the most recent periods was uneven: $101,317 for the quarter ended June 30, 2025, $187,559 for September 30, 2025, $45,100 for December 31, 2025, and $26,143 for March 31, 2026. At March 31, 2026, total assets were $167,105, total liabilities were $5.0 million, shareholders' equity was negative $4.8 million, and cash was $29,346. Inventory fell to $97,539 at March 31, 2026 from $164,651 at June 30, 2025, and accounts payable fell to $132,292 from $1,489,322 over the same period.

Strategy

The company's stated direction is to build a health and biotechnology business through acquisitions, joint ventures and licensing rather than solely internal development. Key elements include the 2021 Purecell arrangement, in which it issued 510,000,000 shares for a contemplated 51% acquisition of an Australian anti-aging institution but accounts for the stake as an equity investment because it lacks significant control. It formed a China joint venture for stem cell-related R&D, production and sales, and entered a cooperation agreement with Dr. David Tsai covering anti-cancer protein peptides, oral insulin and activation technology, with patents in application and products in preparation for production. It also engaged Dr. Kevin Buckman as an advisory committee member to assist GOF Biotechnologies Inc. with new drug approval for oral insulin and Amylase X, compensating him with warrants tied to IND, Phase I, Phase II and Phase III milestones. Filings also reference plans for future acquisitions and private and public issuances of equity and debt securities.

Risks

• Persistent losses and negative operating cash flow — The company has reported net losses and negative operating cash flow in every year shown, including a $719,119 net loss and -$332,862 operating cash flow in 2025.
• Negative shareholders' equity and limited cash — At March 31, 2026 shareholders' equity was negative $4.8 million and cash was only $29,346 against $5.0 million of total liabilities, creating dependence on external financing.
• Dependence on early-stage technologies and partners — Stated peptide, oral insulin and stem cell initiatives are in patent application or pre-production stages and rely on third parties such as Dr. Tsai, Dr. Buckman / GOF Biotechnologies, Brilliant Healthcare and Purecell.
• Lack of control over the Purecell investment — The company issued 510,000,000 shares for a contemplated 51% of Purecell but accounts for the stake only as an equity investment because it does not have significant control, leaving management without operational authority over that asset.

Outlook

Management describes its plans as including completing acquisitions and pursuing future private and public issuances of equity and debt securities. The filings state that several patents are in the application process and several products are in preparation for production, tied to anti-cancer protein peptides, oral insulin and activation technology. No specific revenue, earnings or cash flow guidance is given in the excerpts, and the company disclaims any obligation to update forward-looking statements.